Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 10/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | F9 | P00740 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037113 | 0.95 | LIMK1 (0.49) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL24619537 | 0.91 | LIMK1 (0.54) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL753413 | 0.91 | LIMK1 (0.54) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL755297 | 0.91 | LIMK1 (0.54) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL1230128 | 0.91 | LIMK1 (0.57) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL23555670 | 0.91 | LIMK1 (0.57) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL18429798 | 0.91 | LIMK1 (0.57) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL18470285 | 0.91 | LIMK1 (0.57) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL23555984 | 0.91 | LIMK1 (0.57) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL18470271 | 0.91 | LIMK1 (0.57) | LIMK1PIK3CAPI4KAPI4KBF9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187493-B2 | Heterocyclic compound and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187493-B2 | Heterocyclic compound and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150218185-A1 | Heterocyclic Compound And Use Thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150218185-A1 | Heterocyclic Compound And Use Thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218185-A1 | Heterocyclic Compound And Use Thereof | CCNE1, CRY1, CCNE2 | LIMK1 1164/4885PIK3CA 2634/4885PI4KA 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.